NCT02852486View on ClinicalTrials.gov

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2024

Conditions
Leukemia, Chronic Myeloid
Interventions
DRUG

Pioglitazone 30 Mg Oral Tablet

30 mg/day, orally, for 3 months, before imatinib discontinuation

OTHER

imatinib discontinuation

imatinib discontinuation after 3 months of pioglitazone

Trial Locations (1)

13083-868

Centro de Hematologia e Hemoterapia - Universidade Estadual de Campinas, Campinas

All Listed Sponsors
lead

University of Campinas, Brazil

OTHER

NCT02852486 - Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response | Biotech Hunter | Biotech Hunter